Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study
JCO Global Oncology · 2025
DOI: 10.1200/go-24-00431 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Evelyn Lilian Beas-Lozano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Metastatic urothelial carcinoma (mUC) poses a challenge to health care systems, given its treatment complexity and mortality. We aimed to describe the characteristics, treatment patterns, and survival outcomes of Mexican patients with mUC. METHODS A retrospective study was conducted across eight centers for adults with mUC from January /2001 to December 2021. We recorded medical history, eligibility for first-line platinum therapy, treatment lines received, and access to novel drugs. Descriptive statistics were used and survival analysis, including Kaplan-Meier curves and Cox proportional hazards model, was performed. RESULTS We identified 379 patients with mUC; 37 were excluded, and 76% was male, with a median age of 67 years. The median follow-up was 8.4 months. Among those who received a first-line treatment (65%), cisplatin-based chemotherapy (45%) was the most common followed by carboplatin (39%). Causes of cisplatin ineligibility were Eastern Cooperative Oncology Group ≥2 (41%) and glomerular filtration rate
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Instituto Nacional de Cancerologia, Mexico City, Mexico.
- Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico.
- Hospital Universitario "Dr José Eleuterio González," Monterrey, Mexico.
- Medica Sur, Mexico City, Mexico.
- Centro Oncologico Estatal ISSEMYM, Toluca, Mexico.
ORCID-Profile: Yuly A Remolina-Bonilla, Rosa Caballero, Nora Sobrevilla-Moreno, Omar Alejandro Zayas-Villanueva, Saul Campos-Gomez, Luis Arturo Cardoso-Aparicio, Maria T Bourlon
Zitieren
APA
Beas-Lozano, E. L., Remolina-Bonilla, Y. A., Caballero, R., Sobrevilla-Moreno, N., Perez-Perez, P., Díaz-Alvarado, M. G., Zayas-Villanueva, O. A., Martinez-Castañeda, E. A., Campos-Gomez, S., Cardoso-Aparicio, L. A., Mendoza-Oliva, D., & Bourlon, M. T. (2025). Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study. JCO Global Oncology. https://doi.org/10.1200/go-24-00431
Vancouver
Beas-Lozano EL, Remolina-Bonilla YA, Caballero R, Sobrevilla-Moreno N, Perez-Perez P, Díaz-Alvarado MG, et al. Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study. JCO Global Oncology. 2025. doi:10.1200/go-24-00431
BibTeX
@article{BeasLozano2025,
author = {Beas-Lozano, Evelyn Lilian and Remolina-Bonilla, Yuly A and Caballero, Rosa and Sobrevilla-Moreno, Nora and Perez-Perez, Perla and Díaz-Alvarado, Maria Guadalupe and Zayas-Villanueva, Omar Alejandro and Martinez-Castañeda, Erika Adriana and Campos-Gomez, Saul and Cardoso-Aparicio, Luis Arturo and Mendoza-Oliva, Dolores and Bourlon, Maria T},
title = {Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go-24-00431}
}
EUVIMED